UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma

UniQure is ready to put its Huntington’s disease gene therapy through an advisory committee meeting—even as the broader rare disease space has been put on edge by recent FDA scrutiny of assets by Replimune and Capricor.